Liberation Day, One Year On: How Australia's 10% Tariff Played Out

On April 2, 2025, Donald Trump stood in the White House Rose Garden holding a placard with tariff rates for 185 countries. Australia's number was 10%. It was the floor. Every country that wasn't getting a specific punitive rate received 10%, and Australia, as the United States runs a trade surplus in goods with it, landed at the bottom of the list.

A year on, that 10% looks better than what happened to most of the world. China got 145%, the EU got 20%, Japan 24%, South Korea 25%. Frankly, Australia's position as a minor US trade partner with a services-heavy export base meant the reciprocal formula produced the mildest possible outcome. That is a structural feature, not a diplomatic achievement, and it is worth keeping that distinction clear before anyone starts crediting Canberra's trade negotiators.

What Actually Changed for Australian Exporters

The sectors that felt 10% most directly were the ones already selling into the US market at volume. Australian beef exporters, the northern processors supplying high-grade cuts to US restaurant chains, absorbed the tariff impact through compressed margins in the first two quarters. Wine exports, already under pressure from the post-China rebalancing, faced an additional 10% on top of existing costs. Aluminium was complicated further by separate Section 232 metals tariffs that preceded Liberation Day.

The United States Studies Centre, reviewing the one-year data this week, described Australia as sitting in an "outlier" position globally, not as the 10% was painless, but as the relative position compared to major competitors in the US market improved. Australian beef found itself at 10% while Brazilian beef faced higher rates. That competitive realignment is real, even if it was entirely accidental.

Services exports, which make up the majority of Australia's US trade relationship, were not subject to the tariff regime at all. University enrolments, legal services, consulting fell outside the scope of Liberation Day entirely. The tariff order targeted goods, and Australia's trade exposure was structurally limited from the start.

The New Complication: Pharmaceutical Tariffs

Just as businesses were settling into the year-old tariff environment, Trump announced last week that pharmaceutical exports from Australia would face a 100% tariff. The US Trade Representative's office had flagged Australia's Pharmaceutical Benefits Scheme in its annual trade barriers report. The PBS price control system, which keeps drug costs low for Australian consumers, has long irritated US pharmaceutical companies who argue it amounts to a subsidy that undermines their pricing power globally.

CSL, Australia's largest pharmaceutical exporter, said it was reviewing the implications but did not expect material impact in the short term. Health Minister Mark Butler said "the PBS is not subject to negotiation." A 100% tariff on pharmaceutical goods creates a different kind of trade pressure than the 10% base rate. It is punitive rather than baseline, and it targets an industry where Australia punches well above its weight in global exports.

The Liberation Day tariffs were sold as a negotiating tool. A year later, the 10% rate hasn't come down. The pharmaceutical tariff suggests the trade pressure is still escalating rather than finding a floor. To be blunt, there is no obvious mechanism by which Australia satisfies the US demand. Removing PBS pricing would require legislation and would be politically catastrophic domestically.

Where the Data Points

The Economist's assessment, published this week, is that Liberation Day has reshaped trade, but not as Trump intended. Global trade flows have shifted, with some countries gaining from US import substitution and others losing. Australia sits in neither category strongly. Its 10% rate was low enough to prevent major trade diversion but high enough to erode margin on already price-sensitive commodity exports.

Oxford Economics puts the GDP drag at around 0.3% over five years, modest but compounding. The figure doesn't include second-order effects from a global slowdown in trade investment, which is harder to model but clearly real. Australian business confidence surveys in Q1 2026 cited trade policy uncertainty as the second-most-common risk factor after the Iran situation and its impact on energy prices.

The 66-country digital trade pact signed on March 28, covering data flows, digital service standards, and intellectual property, represents the kind of multilateral workaround that trade economists have been pushing for since the tariffs landed. Whether it provides meaningful relief for Australian exporters depends on implementation details that haven't been published yet.

One year on: Australia avoided the worst of Liberation Day but hasn't escaped it. The pharmaceutical tariff is a reminder that the baseline 10% was always a starting point, not a settlement.